Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550197 | 0.82 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL15804402 | 0.82 | NPSR1 (0.34) | — | |
| SCHEMBL4550372 | 0.78 | L3MBTL1 (0.34) | LMNASMN1; SMN2 | |
| SCHEMBL27769695 | 0.78 | KDM4E (0.34) | LMNASMN1; SMN2 | |
| SCHEMBL3419927 | 0.77 | PIK3CD (0.52) | LMNASMN1; SMN2PARP1 | |
| SCHEMBL23278023 | 0.76 | ATM (0.42) | LMNASMN1; SMN2 | |
| SCHEMBL19543661 | 0.75 | HTR7 (0.34) | — | |
| SCHEMBL11840677 | 0.75 | — | — | |
| SCHEMBL12092353 | 0.75 | HTR7 (0.34) | — | |
| SCHEMBL19543019 | 0.75 | HTR7 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | LMNA 4109/4885SMN1; SMN2 3216/4885PARP1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.